

Key Trend Revolutionizing the Atryn Market in 2025: Increase In Chronic Conditions Driving Growth

The Business Research Company's Atryn Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, January 22, 2025
/EINPresswire.com/ -- Updated 2025
Market Reports Released: Trends,
Forecasts to 2034 – Early Purchase
Your Competitive Edge Today!



The <u>Atryn market</u> has experienced considerable growth in recent years. Starting from \$XX million in 2024, it is expected to peak at \$XX million in 2025, reaching a compound annual growth rate CAGR of XX%. Factors like an amplified demand for antithrombin products, surge in



You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs" The Business Research Company thromboembolic disorders, ascension in hereditary antithrombin deficiency, and the rise of rare diseases awareness have been contributing to the historical growth in the market.

Additionally, the market has the potential to grow to \$XX million by 2029 at a compound annual growth rate CAGR of XX%. The increased use of antithrombin, proliferating

coagulation diseases, rise in chronic conditions, and surge in surgical procedures, coupled with an escalation in diagnostic kits usage are paving the path for this growth.

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19978&type=smp).

What are the primary growth drivers in the Atryn Market?

The Atryn market's rise is primarily fueled by the increasing cases of chronic conditions that usually require long-term treatment or management. Examples include patients experiencing continuous health issues, the aging population, unhealthy lifestyles, and improved healthcare

access and management. A significant driving force in this market is Atryn, a recombinant antithrombin therapy developed to help patients with chronic conditions by preventing harmful blood clots, reducing severe complications, and improving long-term health outcomes.

For instance, in April 2022, according to a report published by the National Association of Chronic Disease Directors NACDD, almost 60 percent of adult Americans have at least one chronic disease, and approximately 40% have multiple chronic conditions MCC. As a result, chronic conditions are expected to cost the US economy \$2 trillion annually or \$8,600 per person by 2030. Hence, the escalation in chronic diseases is a driving force in the Atryn market.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/atryn-global-market-report

Who are the significant players in the Atryn Market?

Some of the key players operating in the Atryn market include rEVO Biologics Inc. Being a chief firm in the field, it is expected that these companies will keep striving and contributing to the overall growth of the Atryn market.

What is the emerging trend in the Atryn Market?

One major trend is the development of contract development and manufacturing organizations CDMOs that specialize in producing therapeutic proteins, primarily through cell culture techniques. For instance, in October 2023, LFB Biomanufacturing launched a project to enlarge its bioproduction capacity in France, furthering treatments for rare diseases, and boosting the nation's biomanufacturing sector.

How is the Atryn Market segmented?

The Atryn market is segmented as follows:

- 1 By Route of Administration: Intravenous IV Administration, Subcutaneous SC Administration
- 2 By Distribution Channel: Direct Sales, Retail Pharmacies, Online Pharmacies
- 3 By Application: Hereditary Antithrombin Deficiency, Acquired Antithrombin Deficiency, Other Thrombosis-related Conditions
- 4 By End-User: Hospitals, Specialized Clinics, Home Care

What are the regional insights in the Atryn Market?

In the global landscape, North America held the largest market share in 2024. Other regions explored in the Atryn market report include Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Surgery Devices And Equipment Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/cardiovascular-surgery-devices-and-

equipment-global-market-report

Cardiovascular Medical Lasers Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/cardiovascular-medical-lasers-global-market-report

Cardiovascular Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Equipped with 1,500,000 datasets, extensive secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company/ YouTube: https://www.youtube.com/channel/UC24 fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook X

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/779200379

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.		